Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AI Health Technology Limited
智慧健康科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1715)

PROPOSED TERMINATION OF EXISTING SHARE OPTION SCHEME AND ADOPTION OF NEW SHARE OPTION SCHEME

On 21 April 2026, the Board resolved to propose the termination of the Existing Share Option Scheme and the adoption of the 2026 Share Option Scheme for the approval by the Shareholders at the AGM.

THE EXISTING SHARE OPTION SCHEME

The Existing Share Option Scheme was adopted by the Company on 24 June 2018 and is valid and effective for a period of 10 years from the date of adoption. It is proposed that the Existing Share Option Scheme will be terminated upon adoption of the 2026 Share Option Scheme.

As at the date of this announcement, there are 6,000,000 outstanding share options, entitling the holders thereof to convert into an aggregate of 6,000,000 Shares upon exercise of the share options. All the 6,000,000 share options were granted under the Existing Share Option Scheme and there are no other share options granted. No share options under the Existing Share Option Scheme have been exercised, lapsed or cancelled since its establishment. The outstanding share options granted under the Existing Share Option Scheme will remain valid and exercisable in accordance with their terms after adoption of the 2026 Share Option Scheme, though no new share options may be granted under the Existing Share Option Scheme after adoption of the 2026 Share Option Scheme.

PROPOSED ADOPTION OF THE 2026 SHARE OPTION SCHEME

The amendments of Chapter 17 of the Listing Rules have taken effect from 1 January 2023. In this connection, the Company proposes to terminate of the Existing Share Option Scheme and adopt the 2026 Share Option Scheme, which will be valid for a period of 10 years from the date of adoption of the 2026 Share Option Scheme. The provisions of the 2026 Share Option Scheme will comply with the requirements of amended Chapter 17 of the Listing Rules which has taken effect from 1 January 2023.

The adoption of the 2026 Share Option Scheme is conditional upon:

(a) the Listing Committee granting approval for the listing of, and permission to deal in, such number of Shares representing the scheme mandate limit under the 2026 Share Option Scheme to be issued by the Company pursuant to the exercise of the Option(s) in accordance with the terms and conditions of the 2026 Share Option Scheme; and

(b) the passing of the necessary resolutions by the Shareholders at the AGM to approve the termination of the Existing Share Option Scheme and the adoption of the 2026 Share Option Scheme, and authorise the Directors to grant Option(s) under the 2026 Share Option Scheme and issue Shares pursuant to the exercise of any Option(s) granted.

Application will be made to the Stock Exchange for the approval for the listing of, and permission to deal in, the Shares to be issued pursuant to the exercise of the Option(s) granted under the 2026 Share Option Scheme.

GENERAL

A circular containing, among other matters, details relating to the termination of the Existing Share Option Scheme and the adoption of the 2026 Share Option Scheme, and the notice convening the AGM will be despatched to the Shareholders in accordance with the requirements of the Listing Rules in due course.

DEFINITION

"2026 Share Option Scheme"	the share option scheme of the Company proposed to be approved and adopted by the Shareholders at the AGM
"AGM"	the forthcoming annual general meeting of the Company to be convened and held to consider and, if thought fit, approve, among other things, the proposed termination of the Existing Share Option Scheme and the adoption of the 2026 Share Option Scheme
"Board"	the board of Directors
"Company"	AI Health Technology Limited, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Stock Exchange (Stock Code: 1715)
"Director(s)"	the director(s) of the Company
"Existing Share Option Scheme"	the share option scheme adopted by the Company on 24 June 2018

"Listing Committee"	the Listing Committee of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended from time to time
"Option(s)"	share option(s) to subscribe for Shares to be granted pursuant to the 2026 Share Option Scheme
"Share(s)"	the ordinary share(s) of HK$0.001 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited

By order of the Board
AI Health Technology Limited
Zhao Jie
Chairman of the Board and Executive Director

Hong Kong, 21 April 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Zhao Jie, Madam Maeck Can Yue and Mr. Wu Huizhang and the independent non-executive Directors of the Company are Mr. Shen Shujing, Mr. Lin Dongming and Ms. Zhang Yuanjie.